A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Perren, Timothy; Marie Swart, Ann; Pfisterer, Jacobus; A. Ledermann, Jonathan; Pujade-Lauraine, Éric; B. Kristensen, Gunnar; S. Carey, Mark; Beale, Philip; Cervantes, Andrés; Kurzeder, Christian; du Bois, Andreas; Sehouli, Jalid; Kimmig, Rainer; Stähle, Anne; Collinson, Fiona; Essapen, Sharadah; Gourley, Charlie; Lortholary, Alain; Selle, Frédèric; R. Mirza, Mansoor; Leminen, Arto; Plante, Marie; Stark, Dan; Qian, Wendi; Parmar, Mahesh; M. Oza, Amit

doi:10.1056/nejmoa1103799

Public

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Published in New England Journal of Medicine • Dec 28, 2011

Authors:

Timothy Perren

Ann Marie Swart

Jacobus Pfisterer

Abstract

BACKGROUND: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. METHODS: We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or ...

Subject

Medicine

Bevacizumab

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!